Skip to main content

Table 3 Comparisons of stage of chronic kidney disease between baseline and post

From: Effect of metformin monotherapy on cardiovascular diseases and mortality: a retrospective cohort study on Chinese type 2 diabetes mellitus patients

Stage of CKD (%, n/N) Full cohort with complete case Propensity score-matched cohort
MM group Control group P value MM group Control group P value
Stage 1 (baseline) to stage 2 or above (post) 21.98 % (624/2839) 21.72 % (260/1197) 0.856 23.26 % (258/1109) 21.07 % (237/1125) 0.211
Stage 2 (baseline) to stage 3 or above (post) 10.62 % (431/4058) 6.89 % (156/2 264) <0.001* 11.09 % (223/2011) 6.66 % (132/1981) <0.001*
Stage 3 (baseline) to stage 4 or above (post) 10.74 % (64/596) 9.73 % (33/339) 0.629 11.43 % (32/280) 9.18 % (27/294) 0.376
Total 14.93 % (1119/7493) 11.82 % (449/3800) <0.001* 15.09 % (513/3400) 11.65 % (396/3400) <0.001*
  1. MM metformin monotherapy, CKD chronic kidney disease, eGFR estimated glomerular filtration rate
  2. Stage 1 CKD (eGFR ≥90 ml/min/1.73 m2); Stage 2 CKD (eGFR ≥60 & <90 ml/min/1.73 m2); Stage 3 CKD (eGFR ≥30 & <60 ml/min/1.73 m2)
  3. Stage 4 CKD (eGFR ≥15 & <30 ml/min/1.73 m2); Stage 5 CKD (eGFR <15 ml/min/1.73 m2)
  4. * Significant with p value <0.05 by Chi-square test